Trial reportJournal of cosmetic dermatology2025
Efficacy of Incobotulinumtoxin A on Maskne: Evaluation in a Prospective, Single-Center, Placebo-Controlled, Double-Blind Study.
Trial report in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSkin quality affects both external perception and psychological well-being. A decline in skin quality, as seen in acne tarda or due to prolonged mask use, especially in healthcare professionals, can be reflected in emergent perceptual category (EPC) parameters. During the COVID-19 pandemic, this led to an increase in mask-induced acneiform eruptions, commonly referred to as "maskne." Intradermal application of Incobotulinumtoxin A (INCO) may improve skin quality, but data in maskne patients are limited.
aimsTo evaluate the efficacy of intradermal INCO on skin quality in women with maskne. PATIENTS/
methodsIn a prospective, randomized, double-blind, placebo-controlled trial, 36 women with maskne received intradermal INCO (20 U) or placebo (2:1) in the mid and lower face. Skin roughness (SEr), sebum level, pore size, and erythema index were measured over 112 days using biophysical tools. Patient and expert assessments were recorded via Global Impression of Change Scale (GICS).
resultsThirty-three participants completed the study. The INCO group showed significantly greater SEr improvement than placebo on days 28, 56, 84, and 112. Sebum level decreased significantly by day 28 (-19.27 μg/cm
conclusionIntradermal injection of INCO represents a promising approach for managing mask-associated skin conditions ("maskne"). While further investigations are necessary to fully establish its benefits, the present study offers encouraging evidence supporting its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.